Characterization of the self-association of human interferon-α2b, albinterferon-α2b, and pegasys.
暂无分享,去创建一个
Walter F. Stafford | David B. Hayes | D. Hayes | W. Stafford | Yi-Ming Li | Mark Hesselberg | Zhuchun Wu | Michael Byrne | Yi-Ming Li | Zhuchun Wu | Michael P. Byrne | Mark Hesselberg
[1] M. Brader,et al. Effects of Non-Covalent Self-Association on the Subcutaneous Absorption of a Therapeutic Peptide , 1998, Pharmaceutical Research.
[2] B. Kuhlman,et al. An exceptionally stable helix from the ribosomal protein L9: implications for protein folding and stability. , 1997, Journal of molecular biology.
[3] H. K. Schachman. Ultracentrifugation in biochemistry , 1959 .
[4] P. Schuck. On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation. , 2003, Analytical biochemistry.
[5] A. Schacher,et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). , 2003, Protein expression and purification.
[6] B. Nardelli,et al. Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys , 2002, Journal of Pharmacology and Experimental Therapeutics.
[7] J. Matthews,et al. The power of two: protein dimerization in biology. , 2004, Trends in biochemical sciences.
[8] M. Fiscella,et al. Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C , 2007, Nature Biotechnology.
[9] Kathryn C. Zoon,et al. Mini ReviewHuman Interferons Alpha, Beta and Omega , 2004 .
[10] P. Schuck,et al. Determination of the sedimentation coefficient distribution by least-squares boundary modeling. , 2000, Biopolymers.
[11] H. Edelhoch,et al. Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.
[12] Zhi-xin Xu,et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.
[13] D. Wyss,et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.
[14] Theodore W Randolph,et al. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony‐stimulating factor , 2003, Protein science : a publication of the Protein Society.
[15] A. Rosenberg,et al. Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.
[16] Anne S De Groot,et al. Immunogenicity of protein therapeutics. , 2007, Trends in immunology.
[17] R. Redfield,et al. A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon-α Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-α-Based Therapy , 2006, Antiviral Therapy.
[18] S. Maher,et al. Interferon: cellular executioner or white knight? , 2007, Current medicinal chemistry.
[19] W. Stafford,et al. Analysis of heterologous interacting systems by sedimentation velocity: curve fitting algorithms for estimation of sedimentation coefficients, equilibrium and kinetic constants. , 2004, Biophysical chemistry.
[20] Yatin R. Gokarn,et al. Hydrodynamic behavior and thermal stability of a PEGylated protein: Studies with hen egg lysozyme , 2003 .
[21] J. Kelly,et al. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. , 2005, Biochemistry.
[22] H. Senn,et al. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. , 2005, Bioconjugate chemistry.
[23] G. Panayotou,et al. Intermolecular Interactions of the p85α Regulatory Subunit of Phosphatidylinositol 3-Kinase* , 1999, The Journal of Biological Chemistry.
[24] R. Chance,et al. Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. , 2001, Critical reviews in therapeutic drug carrier systems.
[25] M. Fiscella,et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. , 2006, Journal of hepatology.
[26] J. Philo. Is any measurement method optimal for all aggregate sizes and types? , 2006, The AAPS Journal.
[27] John P. Gabrielson,et al. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. , 2007, Journal of pharmaceutical sciences.